Literature DB >> 12509944

What's new in the treatment of advanced prostate cancer?

C N Sternberg1.   

Abstract

Increased insight into the biology of prostate cancer and the emergence of new therapeutic strategies and chemotherapeutic agents has changed approaches in treating patients with advanced prostate cancer. After secondary hormonal manipulations, new approaches include: second-line hormonal therapy, chemotherapy, immunotherapy with granulocyte macrophage-colony stimulating factor (GM-CSF) therapy, dendritic cell therapy, gene vaccination therapy, inhibition and/or blockade of growth factor receptors or growth factor receptor pathways, inhibition of neo-angiogenesis and inhibition of invasion and metastases.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12509944     DOI: 10.1016/s0959-8049(02)00665-2

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  5 in total

1.  Restructuring dynamics of DU 145 and LNCaP prostate cancer spheroids.

Authors:  Hong Song; Shamik K Jain; Richard M Enmon; Kim C O'Connor
Journal:  In Vitro Cell Dev Biol Anim       Date:  2004 Sep-Oct       Impact factor: 2.416

2.  Prostate Cancer - What's New?

Authors:  D Doddamani; A Kayastha
Journal:  Med J Armed Forces India       Date:  2011-07-21

3.  Maspin sensitizes prostate cancer cells to doxazosin-induced apoptosis.

Authors:  Anastasios Tahmatzopoulos; Shijie Sheng; Natasha Kyprianou
Journal:  Oncogene       Date:  2005-08-11       Impact factor: 9.867

Review 4.  [Chemotherapy of hormone refractory prostate carcinoma].

Authors:  M P Wirth; J Nippgen
Journal:  Urologe A       Date:  2003-11       Impact factor: 0.639

5.  DUP1 peptide modified micelle efficiently targeted delivery paclitaxel and enhance mitochondrial apoptosis on PSMA-negative prostate cancer cells.

Authors:  Haining Chen; Fengbo Wu; Jing Li; Xuehua Jiang; Lulu Cai; Xiang Li
Journal:  Springerplus       Date:  2016-03-22
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.